Medicxi, the European life sciences investment firm, has demonstrated that there is still a strong appetite for biotech venture financing by being able to raise €400m for a new fund, Medicxi III, in just six weeks. While its previous two funds MV1 and MG1, respectively, focused exclusively on early stage and late stage opportunities, Medicxi III will invest in both early and late stage biopharma companies across the full healthcare continuum from discovery to late stage clinical assets.
“This fundraising has not really been a pitching exercise, it has been more about fund allocation. As soon as we...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


